Contends that specific 5-HT reuptake inhibitors are a new class of compounds whose efficacy needs to be tested in reducing impulsivity, aggressiveness, suicidal behavior, & overeating; in promoting sobriety in alcoholics; in improving memory in patients with alcohol-induced amnestic syndrome; & in the treatment of obsessive-compulsive disorder. In addition, they offer a different side effect profile from tricyclic antidepressants in the treatment of depression. (20 ref)